Leadership/ Governance
Directors
| Representative Director, President & CEO | Koji Tamada, M.D., Ph.D. |
| Director | Tsutomu Tokashiki |
| Director | Hiroko Nagai |
| Outside Director | Philippe Fauchet |
| Outside Director | Nobuo Hanai |
Audit & Supervisory Board Members
| Outside Audit & Supervisory Board Member (full-time) | Kazuyuki Fujiwara |
| Outside Audit & Supervisory Board Member | Hironari Hashioka |
| Outside Audit & Supervisory Board Member | Yukiyasu Nakata |
Advisers
| Adviser | Yukimi Sakoda, M.D., Ph.D. Associate Professor, Department of Immunology, Yamaguchi Graduate School of Medicine |
| Adviser | Sunjin Oh Vice President, BiGEN Co., Ltd. |
Member Profile Details
Member Profile
Representative Director, President & CEO
Koji Tamada, M.D., Ph.D.
1998 Doctor Research Fellow, Mayo Clinic College of Medicine and Science, USA
2002 Assistant Professor, Mayo Clinic College of Medicine and Science, USA
2005 Assistant Professor, School of Medicine, Johns Hopkins University, U.S.A.
2009 Associate Professor, School of Medicine, University of Maryland, USA
2011 Professor, Immunology, Faculty of Medicine and Health Sciences, Graduate School of Medicine, Yamaguchi University (to present)
2016 Director of the company
2020 President, Representative Director, and CEO (to present)
Director, COO
Tsutomu Tokashiki
2014 Representative Director, Leading Valley, Inc.
2015 Joined the company
2018 Division Director and General Manager, Corporate Planning
2019 Director (to present)
2019 Division Director and General Manager, Business Planning
2020 General Manager, Business Planning & Research (to present)
Director, CFO
Hiroko Nagai
2003 Licensed U.S. Certified Public Accountant (Illinois)
2004 Joined Ernst & Young Global Financial Services
2010 Representative of Hiroko Nagai CPA Office
2020 Joined the company, General Manager, Administration (to present)
2020 Director (to present)
Outside Director
Philippe Fauchet
2005 Representative Director and President of Sanofi-Aventis Co., Ltd. (currently Sanofi Co., Ltd.)
2010 Representative Director and President of GlaxoSmithKline GSK Japan
2017 Chairman and Representative Director of GSK Japan
2019 Director of Bonak Co., Ltd.
2020 Director of the Company (to present)
2020 Director of Rezolute Inc. Director (to present)
2022 Outside Director of Luca Science Inc. (to present)
2022 Outside Director, JCR Pharma Co., Ltd. (to present)
Outside Director
Nobuo Hanai
2003 Founded BioWa, Inc. and became President
2012 Representative Director, President and CEO of Kyowa Hakko Kirin Co., Ltd.
2018 Representative Director, Chairman and CEO of Kyowa Hakko Kirin Co., Ltd.
2020 Director of Leave a Nest Capital Co., Ltd. (to present)
2020 Outside Director of Shimadzu Corporation (to present)
2021 Outside Director of Perseus Proteomics Inc. (to present)
Outside Audit & Supervisory Board member (full-time)
Kazuyuki Fujiwara
2011 Executive Officer, Head of Third Block
2012 Executive Officer, Deputy General Manager of Marketing Division, Shinko Asset Management Co., Ltd.
2016 Audit & Supervisory Board Member (full-time), Mizuho Securities Property Management Co., Ltd.
2018 Advisor, Mizuho Securities Property Management Co., Ltd.
2019 Audit & Supervisory Board Member (full-time) of the company (to present)
Outside Audit & Supervisory Board Member
Hironari Hashioka
1998 Registered as an attorney
2004 Outside Director of Golf Digest Online, Inc.
2007 Outside Audit & Supervisory Board Member of UNITED ARROWS LTD.
2008 Partner Attorney, of Vasco da Gama Law Accounting Office established (to present)
2011 Outside Audit & Supervisory Board Member of AP Company, Ltd.
2011 Outside Audit & Supervisory Board Member of Trenders Co., Ltd. (to present)
2014 Outside Audit & Supervisory Board Member of I-FREEK MOBILE INC.
2015 Outside Audit & Supervisory Board Member of the Company (to present)
2017 Outside Audit & Supervisory Board Member of Locoguide Inc.
2018 Outside Director of Locoguide Inc.
2021 Outside Director of Kufu Company Inc. (to present)
Outside Audit & Supervisory Board Member
Yukiyasu Nakata
1999 Registered as a certified public accountant
2001 Joined PwC Tax Accountant Corporation
2009 Registered as a certified public tax accountant
2017 Representative of Yukiyasu Nakata Accounting and Tax Office established (to present)
2018 Director of Melk Co., Ltd. (Currently Cocorport Inc.)
2019 Audit & Supervisory Board Member of the Company (to present)
2022 Audit & Supervisory Board Member of Promat Japan Co., Ltd. (to present)
Governance
Basic Principles
Our company seeks to improve management efficiency as well as the soundness, transparency, and compliance of our operations. We work to increase corporate value based on the management principle of “meeting the expectations of patients, staff, shareholders, and society by developing innovative therapies and growing sustainably as a company.”
Board of Directors
We decide on important matters related to the company’s operations and matters stipulated by law at the Board of Directors’ meeting, which is in principle held once a month and as necessary (i.e., an extraordinary meeting of the Board). In addition, all Audit and Supervisory Board Members attend the Board of Directors’ meetings to monitor the directors’ execution of operations. An individual who has experience in and vast knowledge regarding the management of a pharmaceutical company is invited as an independent director to promote the creation of a system that enables decision-making on operations based on a wider perspective and outside management oversight.
Audit and Supervisory Board and its members
We have chosen to be a Company with an Audit and Supervisory Board under the Companies Act. This Board meets twice a month and as necessary (i.e., an extraordinary meeting of the Board). In addition, the Audit and Supervisory Board members also attend other important meetings in addition to the Board of Directors’ meetings to ascertain the company’s status through discussions with management team. This system allows us to exercise monitoring functions over management.
Management Meeting
We hold Management Meetings attended by all directors and research advisors once a month to; 1) ascertain the status of operations and issues such as whether check and balances are functioning effectively in accordance with the Rules on Administrative Authority and the Rules of Division of Duties; 2) discuss laws and regulations that apply to the industry to which we operate; 3) determine appropriate responses to supervisory authorities; and 4) craft and implement campaigns to raise awareness regarding compliance.
Compensation Committee
Our company has established a Compensation Committee as an advisory body to maintain and enhance fairness, transparency, and objectivity of procedures to determine directors’ compensation. This committee meets once a year (i.e., the routine meeting of the compensation committee) and as necessary. The Board of Directors respects the reports of the Compensation Committee and determines the directors’ compensation.
Conflict of Interest Committee
Our company has established a Conflict of Interest Committee as an advisory body to ascertain and determine conflicts of commitment and conflict-of-interest transactions. This committee meets once every three months and as necessary to investigate whether conflict-of-interest transactions are occurring and to restrain any such transactions. If conflict-of-interest transactions and related-party transactions are to be conducted, the necessity of those transactions and the appropriateness of the transactions themselves and their terms should be determined by the Conflict of Interest Committee in advance. This committee’s opinions should be respected in subsequent resolutions by the Board of Directors.
Internal Audits
Internal Auditors evaluate the rationality, efficiency, and appropriateness of business activities in compliance with relevant regulations before reporting to the President & CEO to facilitate the prevention of misconduct and mistakes and to help improve operations. The remediation of internal audit findings is periodically reviewed to enhance the effectiveness of audits.
